PIK3CB and acute myeloid leukemia: In this respect, Reikvam, et al. [96] investigated the functional effects on primary AML cells of two mTOR inhibitors (rapamycin, temsirolimus) and two PI3K inhibitors (GDC-0941, 3-methyladenine).